Kristin Yarema
CIK 1803794 · Chief Executive Officer · last filed 2026-08-17
Kristin Yarema is a Chief Executive Officer who has filed 13 SEC Form 4 insider transactions across 3 companies since 2020. The most recent filing, for IMA, was dated Aug 17, 2026. Across all open-market trades the lifetime net is +$489.3K, making them a net buyer over the disclosed history. Current disclosed insider exposure totals $2.1M across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
ATRA price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
12526 HIGH BLUFF DRIVE
SAN DIEGO, CA 92130
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| IMA | Chief Executive Officer | 493,705 | $4.05 | $2.00M | $0 | 4 | 2026-08-17 |
| Poseida Therapeutics, Inc. (PSTX) Delisted | President and CEO | 0 | $9.50 | $0 | $0 | 3 | 2025-01-08 |
| ATRA | Chief Commercial Officer | 6,857 | $8.35 | $57.3K | $489.3K | 6 | 2022-03-03 |
Recent Filings
13 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-08-17 | IMA | Grant (A) | +254,800 | $0 | EDGAR |
| 2026-07-28 | IMA | Mixed | +153,505 | $0 | EDGAR |
| 2026-03-18 | IMA | Grant (A) | +85,400 | $0 | EDGAR |
| 2025-07-30 | IMA | Grant (A) | — | $0 | EDGAR |
| 2025-01-08 | Poseida Therapeutics, Inc. (PSTX) Delisted | Mixed | −615,836 | $0 | EDGAR |
| 2024-01-04 | Poseida Therapeutics, Inc. (PSTX) Delisted | Grant (A) | +250,000 | $0 | EDGAR |
| 2023-04-12 | Poseida Therapeutics, Inc. (PSTX) Delisted | Grant (A) | +356,836 | $0 | EDGAR |
| 2022-03-03 | ATRA | Grant (A) | +45,533 | $0 | EDGAR |
| 2021-06-15 | ATRA | Buy (P) | +34,354 | $500.4K | EDGAR |
| 2021-05-20 | ATRA | Sell (S) | −761 | -$11.1K | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.